- Home
- EXEL vs IVZ Comparison
EXEL vs IVZ Comparison
Compare EXEL & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | IVZ |
|---|---|---|
| Founded | 1994 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.3B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EXEL | IVZ |
|---|---|---|
| Price | $43.76 | $25.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 15 |
| Target Price | ★ $46.50 | $27.43 |
| AVG Volume (30 Days) | 2.1M | ★ 5.8M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | $452,477,000.00 | ★ $5,314,100,000.00 |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $13.13 | $5.83 |
| P/E Ratio | $16.05 | ★ N/A |
| Revenue Growth | N/A | ★ 2.98 |
| 52 Week Low | $33.76 | $14.04 |
| 52 Week High | $48.74 | $29.61 |
Technical Indicators
Market Signals| Indicator | EXEL | IVZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 59.16 |
| Support Level | $43.53 | $25.12 |
| Resistance Level | $44.32 | $27.46 |
| Average True Range (ATR) | 1.34 | 0.79 |
| MACD | -0.20 | 0.16 |
| Stochastic Oscillator | 5.54 | 80.36 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).